Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patientsXu Yang, Haitao Zhao, Linzhi Zhang et al.|Hepatology International|2023Cited by 60
Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinomaXu Yang, Haitao Zhao, Baofeng Lian et al.|BMC Medicine|2024Cited by 43
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trialYing–Hong Shi, Enxiao Li, Guohong Han et al.|The Lancet. Gastroenterology & hepatology|2025Cited by 39
Liver bioprinting within a novel support medium with functionalized spheroids, hepatic vein structures, and enhanced post-transplantation vascularizationZhuoran Jiang, Hua Ye, Bao Jin et al.|Biomaterials|2024Cited by 28